ARDX · Ardelyx, Inc.
$5.09
+0.00 (+0.00%)
At close · Jul 21
Market Cap
$1.24B
Shares
247.03M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$407.32M
+22.1%
FY2025
Net Income
-$61.6M
-57.4%
FY2025
Gross Margin
88.64%
+6.5pp
FY2019
Operating Margin
-10.06%
-1.7pp
FY2025
Diluted EPS
-$0.26
-52.9%
FY2025
Operating Cash Flow
-$42.48M
+5.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2029 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1B | $427.68M | $407.32MG | $333.62M | $124.46M | $52.16M | $10.1M | $7.57M | $5.28M | $2.61M | $42M | — | $24.03M | $31.62M | $28.93M | $5.41M | |
| — | $32.05M | $39.54M | $50.56M | $17.8M | $4.12M | $1M | $145K | $600K | $466K | $8.4M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $4.68M | $2.14M | $33.6M | — | $24.03M | — | — | — | |
| — | — | — | — | — | — | — | — | 88.64% | 82.13% | 80% | — | 100% | — | — | — | |
| — | $76.78M | $71.53M | $52.32M | $35.54M | $35.2M | $91.14M | $65.05M | $71.68M | $69.37M | $75.48M | $94.16M | $39.89M | $25.9M | $28.09M | $10.18M | |
| — | — | — | — | — | $76.6M | $72.3M | $33.15M | $24.27M | $23.72M | $23.23M | $18.73M | $13.53M | $7.29M | $3.7M | $4.03M | |
| — | $356.28M | $337.23M | $258.69M | $134.4M | $76.6M | $72.3M | — | — | — | — | — | — | — | — | — | |
| — | — | $3.06M | $2.06M | $1.29M | $1.14M | $2.81M | $2.54M | $2.5M | $2.7M | $2.6M | $1.3M | $800K | $300K | $600K | $675K | |
| — | — | — | — | — | — | $6.2M | — | — | — | — | — | — | — | — | — | |
| — | $93.43M | — | — | — | — | — | — | $95.94M | $93.09M | $98.72M | $112.9M | $53.42M | $33.19M | $31.79M | $14.22M | |
| — | $465.1M | $448.3M | $361.57M | $187.73M | $111.8M | $163.44M | $98.35M | $96.54M | $93.55M | — | — | — | — | — | — | |
| — | -$37.42M | -$40.98M | -$27.95M | -$63.28M | -$63.76M | -$154.35M | -$90.78M | -$91.26M | -$90.95M | -$65.12M | -$112.9M | -$29.39M | -$1.56M | -$2.87M | -$8.81M | |
| — | — | -10.06% | -8.38% | -50.84% | -122.24% | -1528.63% | -1199.05% | -1728.14% | -3488.57% | -155.04% | — | -122.32% | -4.95% | -9.9% | -162.75% | |
| — | — | -$37.92M | -$25.89M | -$61.98M | -$62.62M | -$151.54M | -$88.24M | -$88.76M | -$88.25M | -$62.52M | -$111.6M | -$28.59M | -$1.26M | -$2.27M | -$8.13M | |
| — | $21.51M | $20.1M | $13.01M | $4.95M | $3.4M | $4.5M | $5.1M | $5.73M | $3.53M | — | — | — | — | — | — | |
| — | $8.53M | $8.75M | $9.17M | $6.63M | $1.63M | $687K | $1.57M | $2.35M | $3.19M | $1.96M | $508K | -$261K | $10K | -$52K | -$30K | |
| — | -$57.94M | -$60.63M | -$38.87M | -$65.52M | -$67.2M | -$158.16M | -$94.31M | -$94.64M | -$91.29M | -$63.16M | -$112.39M | -$29.65M | -$3.15M | -$6.42M | -$9.79M | |
| — | $118K | $969K | $266K | $547K | $8000 | $4000 | $2000 | $303K | $4000 | $1.18M | — | -$29K | $67K | $141K | — | |
| — | -$58.06M | -$61.6M | -$39.14M | -$66.07M | -$67.21M | -$158.17M | -$94.31M | -$94.94M | -$91.3M | -$64.34M | -$112.39M | -$29.62M | -$3.21M | -$6.56M | -$9.79M | |
| — | — | -15.12% | -11.73% | -53.08% | -128.85% | -1566.46% | -1245.71% | -1797.77% | -3502.03% | -153.19% | — | -123.29% | -10.16% | -22.69% | -180.87% | |
| — | -$58.2M | -$61.46M | -$39.3M | -$65.79M | -$67.26M | -$158.17M | -$94.34M | -$94.88M | -$91.29M | -$64.32M | -$112.46M | -$29.62M | -$3.21M | — | — | |
| USD/shares | — | — | -$0.26 | -$0.17 | -$0.30 | -$0.42 | -$1.52 | -$1.05 | -$1.47 | — | — | — | — | — | — | — |
| USD/shares | — | — | -$0.26 | -$0.17 | -$0.30 | -$0.42 | -$1.52 | -$1.05 | -$1.47 | — | — | — | — | — | — | — |
| shares | — | — | 241.03M | 235.23M | 219.33M | 158.69M | 104.21M | 89.58M | 64.48M | 56.22M | 47.44M | 40.12M | 22.89M | 10.25M | 1.13M | 864.02K |
| shares | — | — | 241.03M | 235.23M | 219.33M | 158.69M | 104.21M | 89.58M | 64.48M | 56.22M | 47.44M | 40.12M | 22.89M | 10.25M | 1.13M | 864.02K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2012–FY2014: $24K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.56×
P/E (TTM)
—
Biotechnology median 7.21×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Reportable Segment | $407,320,000 | $333,615,000 | $124,456,000 | $52,158,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $377,808,000 | $319,196,000 | $83,276,000 | $15,600,000 | $0 | $0 | $0 | — |
| Asia Pacific | $29,170,000 | $14,341,000 | $41,121,000 | $31,000 | $10,084,000 | $6,765,000 | $5,281,000 | $287,000 |
| North America | $342,000 | $78,000 | $59,000 | $36,527,000 | $13,000 | — | — | $2,320,000 |
| Canada | — | — | — | — | — | $806,000 | $0 | — |
| China | — | — | — | — | — | — | $3,000,000 | — |
| Hong Kong SAR China | — | — | — | — | — | — | $1,500,000 | — |
| Japan | — | — | — | — | — | — | $800,000 | — |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Product | $377,808,000 | $319,196,000 | $82,526,000 | $15,600,000 | $0 | $0 | — | — |
| Product IBSRELA | $274,207,000 | $158,286,000 | $80,062,000 | $15,600,000 | $0 | — | — | — |
| Product X PHOZAH | $103,601,000 | $160,910,000 | $2,464,000 | $0 | $0 | — | — | — |
| Product Supply Revenue | $15,879,000 | $11,649,000 | $6,121,000 | $1,527,000 | $907,000 | $1,501,000 | $322,000 | — |
| Non Cash Royalty Related To Sale Of Future Royalties | $8,545,000 | $2,692,000 | $0 | $0 | — | — | — | — |
| License | $5,088,000 | $78,000 | $35,809,000 | $35,031,000 | $5,013,000 | $706,000 | $4,500,000 | $2,320,000 |
| Collaborative Development | — | — | $0 | $0 | $4,177,000 | $5,364,000 | $459,000 | — |
| Product And Service Other | — | — | — | — | — | — | — | $287,000 |
Key facts
CIK
1437402
CUSIP
039697107
13F (30d)
25 filings
25 filers
Visit website
Investor relations